Sphere Fluidics’ next-generation Cyto-Mine Chroma system due soon

Sphere Fluidics has shared details of its Cyto-Mine Chroma – the second generation of its flagship Cyto-Mine platform – which is due to launch in the first quarter of 2025.

Cyto-Mine Chroma builds on the original Cyto-Mine platform’s ability to leverage picodroplet technology to encapsulate single cells, assess cellular function, and isolate target cells for downstream expansion or analysis.

The new Chroma system will maintain Cyto-Mine’s best-in-class throughput enabling functional screening of millions of cells per hour while expanding its multiplexing capabilities to allow researchers to conduct multiplexing in a single droplet.

This, and the upgrade to a four-colour laser and detector system, significantly expands the utility of the original, single-laser Cyto-Mine platform by increasing the number of targets that can be analysed for each encapsulated cell.

Dale Levitzke, CEO, Sphere Fluidics, said: “We have developed Cyto-Mine Chroma to revolutionise functional single cell screening workflows – it marks a significant milestone as part of our long-term vision for success and leadership in the single cell analysis field.

“The new Chroma system is a direct result of working closely with our customers to understand their requirements and how our microfluidic technologies can best support these, now and in the future.”